Olfen Depotabs (Diclofenac Sodium)

Diclofenac sodium works by inhibiting the cyclooxygenase enzymes COX‑1 and COX‑2, which are essential for converting arachidonic acid into prostaglandins. Lower prostaglandin levels diminish inflammation, pain signaling, and fever, providing symptomatic relief at the site of injury or disease.

The appropriate dose of Olfen Depotabs is determined by the prescribing healthcare professional based on the patient’s specific condition, severity, age, and renal or hepatic function. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

Diclofenac sodium should be used during pregnancy or lactation only if clearly needed and after a risk‑benefit assessment by a qualified clinician. In the first trimester, NSAIDs may affect fetal development, and they can pass into breast milk, potentially impacting the infant.

To place an order, visit the product page for Olfen Depotabs on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Olfen Depotabs (diclofenac) offers potent anti‑inflammatory and analgesic effects comparable to ibuprofen or naproxen, but it may have a higher risk of gastrointestinal and cardiovascular adverse events at equivalent doses. Choice of NSAID depends on individual patient risk factors, therapeutic goals, and clinician preference.

Olfen Depotabs should be stored at temperatures below 25 °C, in a dry place away from direct sunlight. Keep the tablets in the original container to protect them from moisture and humidity, and ensure they are out of reach of children.

Olfen Depotabs is taken orally with a full glass of water. It can be taken with or without food, although taking it with meals may reduce gastrointestinal discomfort. Swallow the tablet whole; do not crush, chew, or split unless specifically instructed by a healthcare professional.

Serious risks include gastrointestinal bleeding or ulceration, severe liver injury, acute kidney failure, and increased cardiovascular events such as heart attack or stroke. Patients should be monitored for signs of these conditions, especially if they have pre‑existing risk factors.

Olfen Depotabs should be avoided in individuals with known hypersensitivity to diclofenac or other NSAIDs, active gastrointestinal ulceration, severe heart failure, uncontrolled hypertension, significant renal or hepatic impairment, and in patients in the third trimester of pregnancy unless deemed essential by a physician.